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Emerging nanotechnologies have, and will continue to have, a major impact on the pharmaceutical industry. Their inﬂuence
on a drug’s life cycle, inception to delivery, is rapidly expanding. As the industry moves more aggressively toward continuous
manufacturing modes, utilizing Process Analytical Technology (PAT) and Process Intensiﬁcation (PI) concepts, the critical role of
transportphenomenabecomeselucidated. Theabilitytotransferenergy, mass,andmomentumwithdirected purposeful outcomes
is a worthwhile endeavor in establishing higher production rates more economically. Furthermore, the ability to obtain desired
drug properties, such as size, habit, and morphology, through novel manufacturing strategies permits unique formulationcontrol
for optimum delivery methodologies. Bottom-up processing to obtain nano-sized crystals is an excellent example. Formulation
and delivery are intimately coupled in improving bio-eﬃcacy at reduced loading and/or better controlled release capabilities,
minimizing side aﬀects and providing improved therapeutic interventions. Innovative nanotechnology applications, such as
simultaneoustargeting,imaginganddelivery totumors,arenowpossiblethroughuseofnovelchaperones.Otherexamplesinclude
nanoparticles attachment to T-cells, release from novel hydrogel implants, and functionalized encapsulants.Diﬃcult tasks such as
drug delivery to the brain via the blood brain barrier and/or the cerebrospinal ﬂuid are now easier to accomplish.
1.Introduction
A large number of hydrophobic compounds with potentially
high pharmacological value fail to pass initial screening tests
because of the perception that they will be too diﬃcult to
delivereﬀectivelydue to anticipated formulation limitations.
Fortunately, nanosuspensions of such drugs may be used to
increasebioavailabilityandoﬀeravarietyofdeliveryoptions.
Historically most formulation strategies aim for particle
size reduction [1–4]. Typically these limit the dimensions
obtainable since the strategies use high shear processing of
preformedentities.Toachievenanoscaledimensionsbythese
size reduction technologies (“top down” processing), an
excessive amount of energy and time needs to be expended
[5, 6]. Unfortunately, they often not only proved ineﬀective
but lead to possible product degradation. Because nanosus-
pensions and novel targeting chaperones, for example
T-cells, can deliver much larger amounts of drug in a smaller
volume than the solvent diluted drug systems [1–4, 7–9],
they have a potential advantage as a formulation strategy.
Emerging nanotechnologies are having a major impact
throughout the pharmaceutical industry. The focus here is
on how these techniques inﬂuence delivery strategies and
eﬃcacy through enhancement of the transport phenomena
involved in all phases of a drug’s life cycle. For example, the
ability to obtain desired drug properties, such as size, habit,
and morphology, through novel manufacturing strategies
permits unique formulation control for optimum delivery
methodologies. The ability to transfer energy, mass, and
momentum with directed purposeful outcomes is impera-
tive in establishing higher production rates of these care-
fully engineered nanoparticles at elevated technoeconomic
stature.2 Journal of Drug Delivery
The role of transport phenomena becomes critically
apparent as the industry moves more aggressively toward
continuous manufacturing modes, utilizing Process
AnalyticalTechnology (PAT) and ProcessIntensiﬁcation (PI)
concepts. Although these advances rely upon more eﬀective
sensor-reporter systems, based on nanoprobe technology,
they are not the focus here and therefore will only be brieﬂy
touched upon in the following discussions. The emphasis
is on the clinical aspects that drive all the other phases
needed to get to this stage. That is, once available, these
nanoscale entities can be utilized quite eﬀectively in both
traditional and novel delivery techniques, relying heavily on
in vivo transport capabilities. The topics to be addressed in
the following sections all capitalize on how carefully these
drugs were designed, developed, and engineered for desired
properties and capabilities. Speciﬁcity of uptake, clearance
control, and transport to the brain via the blood brain
barrier, cerebrospinal ﬂuid, or in smart implants are a few
examples.
Currently, there are a number of nanotechnology
drugs in the market [10]. This ﬁrst generation of such
drugs relies mainly on the small size of the particles to
increase the surface area and therefore bioavailability
of poorly soluble drugs, and to a lesser extent in the
structure of the particle for delayed release, and so forth.
Examples of nanotechnology drugs in the US market
include Rapamune
￿/Pﬁzer, Emend
￿/Merck, INVEGA
￿
SUSTENNA
￿/Janssen, all based on Elan’s NanoCrystal
￿
technology. Abraxane
￿/Abraxis Bioscience and Triglide
TM/
Sciele Pharma are also in the US market. In emerging
technologies, the particleshave improved functionalities that
includediagnosis, targeting, and drug delivery functions and
enhance transport and uptake characteristics. The focus of
this paper will be in these emerging technologies rather than
the current status of the market drugs.
The credibilityof thetechniques(topics)being presented
here is established through either prior extensive testing,
preliminary results from proof-of-concept tests, or derived
from analogous successes for what are believed to be realistic
projected applications. Presented here therefore will be
discussions relative to (a) crystal size and morphology
control, via bottom-up processing, for direct use with
traditional delivery methods, (b) simultaneous target-
ing/delivery techniques incorporating novel chaperones
obtained from functionalized surfactant encapsulants and
T-cells, and (c) controlled release using nanotechnology
innovations involving single and multipledruginterventions
and tissue therapies (e.g., angiogenesis, wound healing, and
artiﬁcial organs for autoimmune diseases). In these cases,
attempts are made to identify the underlying fundamental
physicochemical principles/mechanisms associated such
that projected extensions are feasible, and scaleup where
necessary can be accomplished reliably.
2.Techniques/Applications
In the recent article by G. Liversidge [10], as mentioned
previously, a number of speciﬁc pharmaceutical companies
and associated drugs are identiﬁed that combine control-
release and nanotechnologies. This combination is identiﬁed
as a key market driver for this industry. Based upon
documented recent advances and successful applications,
various potentialopportunitiesare outlined.Powerful exten-
sions to many of the concepts and methods mentioned
there are being developed and some are currently being
implemented throughout the industry. For example, the
concept of minitablets has a profound impact on many
release formulations, (i) delayed-, (ii) extended-, and (iii)
pulsitile-release systems.
An objective of ours via this paper is to identify the
importance and eﬀectiveness of nanotechnological inno-
vations on the enhancement of transport processes that
improve therapeutic protocols. Of the techniques being
discussed, the bottom-up method for nanocrystal formation
will be used as an example because it provides the basis
for our ability to carefully engineer the nanoparticles for
the drug delivery protocols. These entities are an essential
component for the clinical implementation of all the trans-
port enhancedtechniquesinuse and/orproposed.Whenever
available, the results from the various levels of experimental
programs executed are presented and discussed, conclusions
drawn, and recommendations for future eﬀorts set forth.
Presented in Table 1 below is an outline of the current
and emerging methods and nanotechnology applications in
drug delivery platforms. These topics will be discussed or
referenced in the sections that follow.
2.1. Formation of Engineered Crystalline Nanoparticles. A
continuous bottom-up approach to the solvent/antisolvent
crystallization process allows precise control of product
properties. Achievement of speciﬁed quality goals associated
with overall performance criteria has been demonstrated
[11–14]. These include crystal habit, morphology, and size
distribution. The technique involves generating a large
number of nucleation sites and limiting subsequent growth.
With this method crystal size control is via molecular
approaches that utilize various mechanistic pathways gov-
erned by transport phenomena, thermodynamics principles,
and/or intrinsic kinetics.
The design and operation of commercial scale crystal-
lizers are optimized based on minimizing the formation
of agglomerates, impurities included within crystals, liquid
entrapped within crystal aggregates, and mother liquor
retained by the crystal cake [15–17]. The various crystal-
lization mechanisms that contribute to the observed phe-
nomenological events and how they aﬀect these objectives
will be addressed throughout this section.
The generation of nanoscale homogeneous regions dis-
persed throughout the active crystallization volume is essen-
tial for the success of this bottom-up process. Estimating
the size of these regions is reasonably straightforward using
proven turbulence calculation algorithms [18–20]. The sig-
niﬁcanceisthatthelengthscaleoverwhichnofurthermixing
takes place is established and thus molecular diﬀusion now
dictates timing for the steps involved in the homogeneous
nucleation and growth processes within these regions. SinceJournal of Drug Delivery 3
Table 1: Current and emerging nanotechnology.
Methods Applications
Current (i) Top down
(ii) Batch manufacturing
(i) Enhanced bioavailability
(ii) Delayed delivery
(iii) Extended delivery
(iv) Pulsitile delivery
Emerging
(i) Targeted delivery
(i) Bottom up (ii) Simultaneous targeted, imaging, and delivery
(ii) Continuous manufacturing (iii) Delivery to the brain (overcoming the Blood Brain Barrier)
(iii) PAT (iv) Delivery through novel targeting chaperons, (example T-cells)
(v) Artiﬁcial organs, tissue therapy, wound healing, and so forth.
hydrodynamics has a signiﬁcant impact upon mass, energy,
and momentum transport rates and reaction proﬁciencyit is
imperative that the role it plays not be underestimated. It is
also essential to identify the energy dissipation mechanisms
present and thereby quantify the intensity of mixing (i.e.,
m a c r o - ,m e s o - ,o rm i c r o - ) ,c o n t a c te ﬃcacy, and associated
level of turbulence with its resultant eddy cascade. The
length scale of the Kolmogorov (i.e., smallest) eddies, when
formed at high energy dissipation levels, can easily be at the
nanoscale. The important point is that the magnitude of this
energy dissipation rate per unit volume establishes both the
time and length scales over which events occur. These can be
key control variables manipulated by mixing intensity once
the thermodynamic state of the working ﬂuid is established
throughotherprocessingvariables. Observedrates arehighly
dependent on the concentration diﬀerences beyond the
solubility limit and hydrodynamic scales. Hence, the local
degree of supersaturation can be used as the primary
metric to account for both the kinetics and thermodynamic
behavior of the system [11, 12, 21, 22].
Crystal characteristics, such as crystal size distribution
(CSD), surface area and topography, morphology, dissolu-
tion rate, and strength (aﬀected by any impurities and ﬂaws
present), depend heavily upon their formation processing
conditions. An inclusion of mother liquor for example
aﬀects not only product quality for its desired applications
but also storage stability, particularly with respect to CSD
and morphology. This is of considerable importance to the
pharmaceutical industry since polymorphic systems exhibit
diﬀerent physicochemical properties due to the existence of
these diﬀerent crystal structures. Polymorphism inﬂuences
the dissolution characteristics, which along with CSD aﬀects
product formulation strategies and bioavailability [1, 2, 11–
14, 23–26].
To understand how to form crystalline nanoparticles
of hydrophobic active pharmaceutical ingredients (APIs)
via this bottom-up process requires knowledge of the
fundamental thermodynamic and rate processes involved in
the generation of solid particles from a liquid phase. This
involvessolubilitylimitsofthetargetspecies(withassociated
degree of supersaturation), nucleation and growth rates, and
turbulence intensity to obtain the requisite mixing levels.
It is the energy dissipation levels developed by turbulence
that determine the appropriate length and time scales
required to control the phenomenological events occurring.
Althoughthesetopicsarediscussedinsomedetailforspeciﬁc
applications elsewhere [11–22], a brief summary of each is
included here for clarity of purpose.
The various aspects and important parameters thataﬀect
the “bottom-up” crystallization process to be discussed are
the following.
(i) Thermodynamics; describesphase characteristics, sol-
ubility limits and phase stability, establishing the
driving force for crystallization.
(ii) Nucleation and crystal growth; related to crystalliza-
tion rates, particle sizes, and crystal structures.
(iii) Complications; describes some of the issues that need
to be addressed in designing a process and getting the
desired product quality.
(iv) Flow Patterns, Mixing, and Transport Phenomena;
describes the role of mixing in crystallization pro-
cesses, relevant to processes that involve mixing of
multiple streams, heating or cooling.
(v) Creating Nanoscale Entities; describes strategies of
achieving mixing in the nanometer scale and tech-
niques used.
(vi) Energy Dissipation; gives an overview of the mecha-
nisms that absorb energy during the process.
2.1.1. Thermodynamics. Generating solids from a liquid
phase is initiated by changes in the thermodynamic state
of the solution, thereby reducing the solubility of the
target species. Initiation may be through temperature adjust-
ment(s), concentration changes, or by altering solution
activity coeﬃcients as in the solvent/antisolvent method.
Phase stability is an important factor in determining both
when and how fast events progress. The Temperature-
Composition phase behavior, see Figure 1,c a nb eu s e d
to illustrate some important concepts. A solubility curve
represents thermodynamic equilibrium between the phases.
Formost liquidsystemswith acompositionand temperature
above its solubility curve a stable unsaturated liquid exists.
Beyond this solubility limit the liquid may not be in
thermodynamic equilibrium with respect to the formation
of the solid phase, that is, it exists as a supersaturated (SS)4 Journal of Drug Delivery
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Figure 1: Solubility Curve and Metastable Zone plotted against
temperature and concentration.
liquid. System behavior can be determined by this degree
of SS since there is a region, referred to as the metastable
zone, where the system may not always be considered
thermodynamicallyunstable.Heterogeneousnucleationsites
arethusnecessary toinitiate theformationofthesolidphase.
However,beyondtheboundaryofthismetastablezone,these
seed nucleation sites are no longer required. In this region a
SS liquid is neither stable nor in equilibrium, and is subject
to spontaneous nucleation and rapid growth of the solids.
Unfortunately, due to the large increase in entropy, some
undesired events may occur. The crystal matrix may have
ﬂaws, such as dislocations, impurity molecules, or liquid
inclusions. When a system exhibits various polymorphs, this
spontaneity could be problematic or beneﬁcial, depending
on the morphology sought and its stability. Since our
objective is to create a large number of nucleation sites and
thereby restrict the ultimate size of the individual particles,
and possibly control morphology, this unstable zone is the
desired initial operational region. To control the nucleation
and growthrates, thestrategy used mustestablish thedesired
supersaturation state, level of energy input, and energy
dissipation mechanisms. The need for the latter two will be
discussed in subsequent sections.
2.1.2. Nucleation and Growth. The degree of supersaturation
inﬂuencestherateoftheindividualstepsinvolvedinforming
the solid as well as which crystal polymorph is formed. In
general, the process proceeds as follows: (1) feed streams
are mixed in a process unit selected to meet required
speciﬁcationsfortheenergydissipation rateperunitvolume.
The time to achieve homogeneity is dependent on diﬀusivity
of the target species and the distance they must travel
within the smallest eddies obtained (see the discussion on
mixing for the role of turbulence and the Kolmogorov
scale); (2) mixing to obtain the desired local degree of
supersaturation, leading to a nucleationrate, which increases
proportionally with SS. The features of the product formed
depends signiﬁcantly on this rate; (3) growth of the nuclei
is by diﬀusion of solute molecules from the bulk solution
to the surface and then along the surface to be integrated
into the matrix. This continues until a limiting particle
size is reached, determined by the magnitude of the shear
force present; (4) further growth is by mechanisms whereby
particles collide and adhere to each other. Particle number
thus decreases with time as the particle size increases.
The ability to create and control a supersaturation
driving force is paramount to having a robust process. It can
be generated by various methods including indirect cooling,
evaporation, adiabatic evaporative cooling, antisolvent addi-
tion and salting out, chemical reactions, and pH adjustment.
Note that temperature changes may be detrimental for
some systems, for example when dealing with protein-
based drugs. Alternative methods most frequently used to
reduce solubility are pH adjustment to the isoelectric point,
increasing ionic strength, addition of nonionic polymers,
and addition of a miscible nonsolvent.
2.1.3. Complications. Many factors can restrict productivity
andpurity.Ofparticularinterestforthebottom-upapproach
are agglomeration, liquid inclusions, and ineﬃcient mother
liquor removal.
Agglomeration. T h ep a r t i c l es i z ec a nc l e a r l yb ea ﬀected by
agglomeration and fracture mechanisms. When growing
crystals collide they may stick together and form new
particles, that is, agglomerates form when the collisions are
inelastic. The strength of the physical bonds thus formed
determines their stability upon further collisions. For the
bottom-up processing to be eﬀective in limiting crystal size
the probability of agglomeration needs to be low. Unfor-
tunately, a large number of small particles are produced
when operating in the unstable supersaturation region and
collisionfrequencyishigh.Tooﬀsetthisconcentrationeﬀect,
it is necessary to limit the time for interaction and/or relieve
SS quickly. Also, a surfactant may be eﬀective in limiting the
probability that the particles will stick to one another.
Liquid Inclusion in Individual Crystals and Agglomerates.
This is particularly undesired when liquid impurities are
present. High growth rates can contribute to increased
amountsofliquidentrappedwithinacrystal.Also,liquidcan
gettrappedbetweencollidingparticlesduringagglomeration
and higher supersaturation levels increase the probability of
that occurrence. Thus high supersaturation can have both
beneﬁcial and problematic outcomes. One can mitigate any
associated problems by limiting the interaction time and/or
relieve the supersaturation condition rapidly.
2.1.4. Flow Patterns, Mixing, and Transport Phenomena.
Mixingatthenanometer scaleoccursasreactants,which may
include several liquid and solid phases, are subjected to high
shear stresses and turbulence. The energy dissipation rate
determineswhetherthe macro-, meso-, ormicromixing level
is attained. The overall mixing process occurs within a ﬂow
ﬁeld continuum which covers the wide range of length and
timescalesindicativeofeachofthesemixinglevels,eachwith
distinct characteristics. For example, consider two miscible
ﬂuids. The large scale distribution by ﬂow patterns thatJournal of Drug Delivery 5
causesgross dispersionis consideredmacromixing. Next,the
breakdown of large eddies into smaller ones via the “eddy
cascade” is termed mesomixing. Fluid engulfment in small
eddies with subsequent laminar stretching of them, where
molecular diﬀusion is now the ﬁnal mechanism to obtain
uniform composition, is referred to as micromixing [18–20].
The length scale for this diﬀusional process is determined
by the size of the smallest eddies formed and is referred
to as the Kolmogorov length scale. Along with time and
kinetic energy scales, each determined by these local ﬂow
conditions alone, (i.e., related to kinematic viscosity and
the energy dissipation rate per unit mass), the so called
Kolmogorovscalesareestablished.Estimating themagnitude
of these Kolmogorov parameters can be accomplished with
reasonable conﬁdence using proven theoretical turbulence
calculations. The signiﬁcance is that the length scale over
which no further mixing takes place is established and
molecular diﬀusion now dictates timing for the necessary
steps involved in the homogeneous nucleation and growth
processes.
These mixing subprocesses generally occur in series,
but often to some extent, in parallel. Turbulent energy
dissipation rates, for example in modiﬁed impinging jet
technologies [11, 12, 27–29], are estimated to be on the
order 107 W/kg and higher when using these micromixing
models. At these levels, rapid micromixing and mesomixing
(on time scales of 4 and 20µs, resp.) are achieved, and the
length scale of the smallest eddies are at the nanoscale. Note
that residence times in many of the microreactors systems
used for PI applications [30], particularly those utilizing
impinging jets, are of the order 1ms and lower.
Incorporating these fundamental principles and using
appropriately designed equipment it is possible to precisely
control each step in the crystallization process. Mixing at the
nanometer scale provides a uniform supersaturation ratio.
The onset of the nucleation process can be manipulated by
controlling the timing and location of the mixing of the
solvent and antisolvent streams that are used to generate
the supersaturated state. This in combination with an evenly
dispersed homogeneous supersaturation ratio results in
uniform crystal growth and stabilization rates.
2.1.5. Creating Nanoscale Entities. The generation of
nanoscale homogeneous regions dispersed throughout
the system is a major requirement for the success of this
bottom-up process. When accomplished, it is reasonable
to consider these regions as nanoreactors. This concept is
ideal for our purposes since both length and time scales
are quite small for the processes involved in creating these
monodispersed nanoparticles. Consequently,it is immaterial
whether or not these regions are stabilized, as for example,
by use of surface active agents.
It is important to reiterate that the length scale over
which no further mixing takes place is established and
molecular diﬀusion now dictates timing for the necessary
steps involved in the homogeneous nucleation and growth
processes. In the absence of seed crystals or other nucleation
sites, a critical number of molecules must collide and remain
aggregated forming stable clusters, (i.e., nuclei). Subsequent
growth requires diﬀusion to and along the surface, followed
by a speciﬁc integration process that incorporates these
molecules into the crystal matrix of a particular polymorph.
The observed crystallization rate is, therefore, highly depen-
dent on length scales and the local degree of supersatu-
ration. The polymorph that is obtained is dependent on
thermodynamic considerations, such as component activity
coeﬃcients (solvent/antisolvent/solute species interactions,
composition/concentrations, and temperature) and entropy
generated due to the spontaneous nature of the process, that
is, rates inﬂuenced by supersaturation ratios.
To generate the high energy dissipation rates used to
produce nanoparticles, many processing techniques utilize
high shear ﬁelds. Jet impingement, on a solid surface or
with another jet, has been shown to be a highly eﬃcient
method [11, 12, 27, 28]. Systems that incorporate high
velocity linear ﬂuid jets that collide can rapidly reduce
the scale of segregation between the streams. High-energy
dissipation is observed because the kinetic energy of each
stream is converted into a turbulent-like motion as the
result of the collision and redirection of the ﬂow within
a very small volume. More thorough discussions on the
phenomenological events, equipment design criteria, and
characterization studies are given elsewhere [11–15, 18–26].
2.1.6. Energy Dissipation. Surface tension and various
molecularforcesbetweenthespeciespresentarekeyvariables
associated with the crystal size distribution. Thus, surface
active agents can play a signiﬁcant role whether as a
contributor to growth mechanisms or as a size stabilizer.
For example, they are involved in self-assembly mechanisms,
and can act as barrier components that restrict transport,
as possible chaperones that target speciﬁc sites during drug
delivery, as sequestering agents to facilitate contact eﬃcacy,
as promoters of interfacial phenomena, and as inhibitors to
agglomeration.
The fraction of the input energy available for for-
mation of surfaces is instrumental in establishing system
eﬃcacy. Performing an energy audit to determine overall
requirements is an essential task for this systems analysis
approach. This entails determining the amount of input
energytransformedintokineticenergyofthejets,identifying
all forms of dissipation (whether desired or not), and
ascertaining the amount stored as internal energy. Although
the system energy requirements are not readily identiﬁed
ap r i o r i , the total energy input and the amount dissipated
and stored are measurable. Estimates of the various losses
occurring can be made, and the energy utilization for
the desired processes can also be estimated. This permits
energy considerations to be used in predicting performance
from the estimated length and time scales obtained. System
validation is accomplished when these length and time scales
can be corroborated with observed kinetics phenomena
[12, 27, 28].
2.1.7. Examples of Successful Applications. Conﬁned imping-
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consistently produce submicron API suspensions via a
continuous process that involves crystallization via the
solvent/antisolvent technique to generate supersaturation
conditions. Microﬂiudics Reaction Technology (MRT) was
selected for this bottom-up processing since it is based on
novel multiple stream inlet capabilities coupled with the
impinging jet concept [11–14, 26]. It is designed to produce
jet velocities and energy dissipation orders of magnitude
higherthanthoseofconventionalimpingingjetreactors.The
technology provides precise control of the feed rates, and
the subsequent location and intensity of mixing of the reac-
tants. It may provide signiﬁcant technical and economical
advantages due to its process intensiﬁcation character that
minimizes energyrequirements, and theprovenscalabilityof
the reactor.
In ourﬁrst proofof conceptstudiesperformed, nanosus-
pensions of several APIs were produced varying the key
parameters of the technology [14]. Five diﬀerent model APIs
were used for testing and were selected to belong to diﬀerent
chemical families that exhibit diﬀerent pharmacological
activities. There were two antibiotics (azithromycin and API-
2), an antihistamine (loratadine), an anticonvulsant (oxy-
carbazepine) and a non-steroidal anti-inﬂammatory (NSAIS,
API-1). The particle size depended on the supersaturation
ratio and energy dissipation expressed as process pressure.
The nanosuspensions were stable with narrow particle size
distributions and median particle sizes in the range of 50–
760nm. This “bottom up” process was compared to a “top
down” process in which drug nanosuspensions were created
as a result of particle size reduction. It was found that the
“bottom up” process was substantially more eﬃcient and
resulted in smaller particles.
This ﬁrst study did not attempt to identify crys-
talline structure and therefore no polymorph selectivity
capabilities were evaluated. To accomplish this, two addi-
tional, more in depth studies were conducted on sin-
gle APIs: Carbamazepine (CBZ), an anticonvulsant, and
Norﬂoxacin (NFN), an antibacterial agent. The details of
the experimental protocols and results are reported in
separate papers, CBZ [12]a n dN F N[ 11]. A few brief
comments are given here to help validate the beneﬁts of
bottom up processing with respect to the stated objectives
of creating carefully engineered particles with “tunable”
characteristics.
The NFN nanosuspensions had narrow particle size
distributions and median particle sizes in the range of
170–350nm depending on the supersaturation ratio and
energy dissipation expressed as process pressure. However,
the particle size was found to be insensitive to the presence
of the surfactant used. The crystalline structure of NFN was
not aﬀected by the processing conditions for this particular
solvent/antisolvent system, but it was diﬀerent than the
initial crystalline structure of the drug. This implies the
product is tunable.
Theparticlehabitwasneedle-shaped. Twomiscibleﬂuids
were used as the solvent (DMSO) and antisolvent (water).
The eﬀect of process pressure (determining the energy
input), the NFN concentration, the supersaturation ratio,
and the presence of surfactant on the particle size and
Table 2: List of various “bottom up” processes and inﬂuence on
particle properties.
Bottom up processes Properties controlled
Crystallization
(i) Size, shape
(ii) Crystalline
structure—Crystalline/amorphous
(iii) Polymorph
Precipitation (i) Size, shape
(ii) Surface area
Encapsulation in
polymers
(i) Size, shape
(ii) API concentration
(iii) Particle nanostructure
Chemical reactions
(i) Size, shape
(ii) Purity
(iii) Surface area
the crystallized material was investigated. Higher pressures
resulted in smaller particle sizes, as did lowering NFN
concentration and supersaturation ratios. The surfactant
that was used (Solutol) did not aﬀect the particle size. The
crystalline structure was not aﬀected by the shear rate of
the process. It was identical to those formed in a beaker
under low shear conditions. However, the crystallite size of
the material decreased threefold from no shear to high shear
conditions.
CBZ was selected as a model system since it is
known to exhibit polymorph multiplicity. Several sol-
vents and antisolvents were used to determine their eﬀect
on the crystalline structure and particle size. CBZ is
also known to form hydrates, therefore both aqueous
and nonaqueous solvent/antisolvent systems were used for
comparison. They were Dichloromethane (DCM)/Hexane,
Poly(ethylene-glycol) (PEG) 300/Water, and Dimethyl sul-
foxide (DMSO)/Water.
The results obtained with respect to processing con-
ditions are consistent with those of the NFN study. Par-
ticle sizes obtained with all bottom up experiments were
consistently in the range of 250–320nm. Unfortunately,
the results obtained with respect to polymorph selectivity
were not as deﬁnitive. What was observed is that the
solvent/antisolvent system does matter, but it is unclear if
the degrees of supersaturation or processing intensity had
signiﬁcant roles in that study. Three diﬀerent morphologies
were detected via XRD patterns and a hypothesis is given to
explain the detailed observations presented there. Although
not conclusive and thus more thorough studies must be
performed,theexplanationsareconsistentwiththoseresults.
Althoughtheemphasisin thepreviousparagraphswasin
crystallization, other processes can be used to manufacture
nanosized materials with tailored properties. Encapsulation
of functional ingredients in polymers is another method,
which will be discussed in more detail in the sections that
follow. Table 2 summarizes the processes used in the bottom
upproductionofnanoparticlesand thepropertiescontrolled
via such methodologies.Journal of Drug Delivery 7
2.2. Simultaneous Targeting/Delivery Techniques. Creative
advances in nanotechnologies, coupled with systems biol-
ogy, has led to novel chaperone systems for simultaneous
targeting/delivery, and in certain instances, enhanced con-
trolled release strategies. The systems selected for illustration
here are (1) polymer nanosuspensions, (2) functionalized
designer surfactant encapsulants, and (3) attachment to T-
cell surfaces.
2.2.1. Polymer Nanosuspensions. The creation and use of
chaperone systems in targeting, drug delivery,and diagnostic
imaging has greatly broadened the applications, and thus
needs, for polymer nanosuspensions. The enhanced surface
to volume ratios provides unique capabilities for function-
alization of the surface for these high degrees of speciﬁcity
requirements.
The intended use of these nanosuspensions dictates
controlofboththemean particlesize anddistribution.These
parameters determine performance and toxicity through the
selectivity and rate ofreceptor-ligand interactions and/or the
ability and rate of cellular uptake. The implementation of
systems that can control nanoscale phenomena is required
and has been reported previously [13]. The techniques
reported there can create nanosuspensions of many diﬀerent
polymer types with varying particle sizes by controlling
the formulation and process variables. These nanosuspen-
sions may also contain encapsulated species via either co-
precipitation or other less eﬃcient cargo loading techniques
that rely upon diﬀusional uptake strategies.
Encapsulation of active pharmaceuticals and contrast
agents within these biocompatible polymers is read-
ily accomplished using bottom-up techniques for co-
precipitation processes that are reproducible and scalable.
Nanosuspensions in the range of 50–500nm with diﬀerent
polymers with high encapsulation eﬃciencies have been cre-
ated successfully. For example, suspensions of poly(epsilon-
caprolactone) (PCL) (a polymer that has been extensively
used for parenteral drug delivery) were created using
MRT (as discussed above in previous sections). By mixing
a 20mg/mL (PCL/acetone) solvent stream with water at
a ratio 1:10 (solvent/antisolvent) a nanosuspension with
a mean particle size of 220nm was prepared. Their size and
spherical habit was conﬁrmed using SEM instrumentation.
2.2.2. Functionalized Designer Surfactant Encapsulants.
There has always been an active interest in targeted drug
delivery to tumors to speciﬁcally kill cancer cells. Ongoing
research in this area has provided signiﬁcant advances due
to the ability to carefully engineer both the vesicle, for its
speciﬁcity and imaging characteristics, and its cargo API.
A collaborative team has developed a highly adapt-
able amphiphilic alternating copolymer system that self-
assembles into micelles for therapeutic delivery applications
in cancer [8, 9]. The synthetic scheme includes the enzy-
matic polymerization of multifunctional linker molecules
(dimethyl 5-hydroxyisopthalate) with poly(ethylene glycol).
This chemoenzymatic synthesis is much faster and more
convenient than an entirely chemical synthesis. Subsequent
synthetic steps have been developed to attach ligands (for
targeting), perﬂuorocarbons (19F MR imaging), ﬂuorescent
dyes (NIRF imaging), and radioiodine (nuclear imaging and
radioimmunotherapy) to the backbone polymer.
Attachment of hydrocarbon or perﬂuorocarbon side
chains provides amphiphilicity to produce the multimodal
self-assembling micelles. Additionally, encapsulation proce-
dures for chemotherapeutic agents, that is, doxorubicin and
paclitaxel, have been established. These unique alternating
copolymer micelle nanoparticles were designed as delivery
vehiclestargeted to human cancercellsexpressing the under-
glycosylated mucin-1 antigen, which is found on almost all
epithelial cell adenocarcinomas, by use of the peptide EPPT,
or the folate receptor (FR) by using folate.
Development of the synthetic schemes has been coupled
with in vitro toxicity tests using various cell viability assays
to minimize the toxic eﬀect of these copolymer structures.
The nontoxic polymers were brought forward into drug
delivery and uptake experiments. Cell death due to dox-
orubicin increased with encapsulation in these alternating
copolymers. Additional slight improvements were observed
when targeting ligands were attached to the encapsulating
polymer. Similar results were obtained with paclitaxel as the
cargo.
Cellular uptake determined by 125I or 3H radioactive
analysis and ﬂuorescence confocal microscopy was also
investigated in other in vitro studies. Microscopy images of
the labeled polymer alone demonstrated that the polymer
was most likelyconﬁned tovesicleswithin thecytoplasmand
not found in the nucleus, whereas encapsulated doxorubicin
was shown to be largely conﬁned to the nucleus. Theoretical
models of polyvalent binding were employed to guide
the design of the targeting polymers. Unfortunately, the
polymers used in this study appeared largely nonspeciﬁc
for the targeted cells when studied in vitro.H o w e v e r ,
the versatility of these polymer constructs suggests that
continuing to optimize for a targeting delivery system for
drugs and imaging agents using this polymer platform could
be extremely beneﬁcial.
2.2.3. Attachment to T-cell Surfaces. Before discussing the
speciﬁcs of the use of T-cells in drug delivery protocols, a
few general comments about the underlying principles are
appropriate. The basis of this approach is attributed to the
new, burgeoning ﬁeld of biohybrid materials which will have
a signiﬁcant impact on the eﬃcacy of drug delivery. This is
in addition to their obvious use in bioimaging, cellular func-
tionalization, immune system and tissue engineering, and
cell-based therapeutics where cell-environment interactions
are critical.
Of particular interest here are synthetic materials systems
such as magnetic micromanipulators, nanoparticulate cel-
lular patches, and functional cell backpacks [31, 32]. These
oﬀer exciting possibilities for symbiosis between synthetic
building blocks and native biological behavior. The key is
the ability to systematically modify the surface of living
cells. This was clearly demonstrated by the collaborative
eﬀorts of the Cohen and Rubner research groups [31]8 Journal of Drug Delivery
with functional polyelectrolyte multilayer (PEM) patches
attached to a fraction of the surface area of living, individual
lymphocytes. These cells remained viable, and with patches
containingmagneticnanoparticlesthecellscouldbespatially
manipulatedusingamagnetic ﬁeld.Sincethepatchesdidnot
completelyoccludethecellularsurface fromthesurrounding
environment a functional payload couldbe attached without
interfering with the cells ability to perform its native func-
tions. This initial work has led to what is now referred to as
cellular “backpacks”, nanoscale thickness, micrometer-sized,
photolithographically patterned heterostructured multilayer
systems capable of noncytotoxically attaching to the mem-
brane of a living cell. It is interesting to note that these
“backpacks” can play an integral part in tissue engineering
applications, such as in cell aggregate self-assembly [32]
which will be discussed brieﬂy in a later section.
To illustrate the use of this concept in a drug delivery
scenario, an extension of this technique was exploited as
follows. In a recently published study, a method of attaching
carefully engineered nanoparticles to the surface of T-cells
was identiﬁed [7]. Although their application was for a cell
therapy approach, the T-cells were used as chaperones for
the stimulant drugs. They designed drug carrying nanoscale
vesicles with lipid characteristics for coupling with the sulfur
containing molecules on T-cell surfaces. In their study the
researchers injected these cargo carrying cells, each with
approximately 100 vesicles loaded with interleukins IL-15
and IL-21, into mice with lung and bone marrow tumors.
Once reaching the tumors these packets gradually degraded
releasing the drugs over a period of one week. Their concept
was forthe drugmoleculesbeing released toreattach tothese
chaperone T-cells, stimulating them to replicate and thus
provide the requisite tissue therapy. The techniques proved
successful in that within 16 days, all tumors in the mice
treated in this fashion disappeared and these mice survived
for the entire 100-day experiment. Mice that received no
treatment died within 25 days and those that received either
T-cells alone or T-cells with injections of interleukins died
within 75 days.
A few details of their procedure are presented here to
stress the relatively straight forward nature ofthese protocols
and instill conﬁdence that the proposed clinical applications
can be realized with a high degree of certainty. Their method
exploits the fact that T-cells, like many cell lines, have high
levels of reduced thiol groups on their surface, and thus
stable coupling of the synthetic drug carrying nanospecies
to them is possible. Speciﬁcally, liposomes and liposome-
like synthetic entities 100–300nm in diameter, with a drug
loaded core and phospholipid exterior layer, were linked to
the cells via the thiol reactive maleimide head-groups. A
simple two-step process achieved the desired conjugation.
The donor cells were ﬁrst incubated with nanoparticles to
accomplishthethiol-maleimidecoupling.Thisisfollowedby
in situ conjugation to thiol-terminated poly ethylene glygol
(i.e., PEGylation) to quench the residual reactive groups
to ensure that only about 20% of the surface thiol groups
were involved with the initial coupling, that is, linked with
approximately 150 nanoparticles. Stable, nontoxic linkages
to live cells were thus accomplished with particles ranging
from simple liposomes to complex multilamellar lipid
nanoparticles or lipidcoatedpolymers. This benign behavior
was anticipated since only 3% of the surface of a typical
7µm diameter T-cell would be blocked by 200nm diameter
particles occupying 150 sites.
These results suggest therapeutic cells are promising
vectors (chaperones) for actively targeted imaging and
drug delivery. Furthermore, the attached entities can be
engineered for controlled release of individual or multiple
drug sequencing capabilities. What can be envisioned is the
useofdiﬀerentvesicleswithspeciﬁctransportordegradation
properties or a vesicle composed of, for example, multiple
polymeric materials, as will be discussed in the following
section devoted to release strategies.
2.3. Controlled Release Using Nanotechnology Innovations.
For a large number of health care/wellness interventions
the controlled release of therapeutic agents is a necessary
strategy. Carefullydesigned APIformulationscan accommo-
date a broad spectrum of requirements. The release concepts
employed range from (i) simplistic steady release rates
{via dissolution, etc.}, (ii) intermittent timed release, (iii)
programmed simultaneous and or sequential release of mul-
tiple species {antigenic drugs and adjuvants},t o( i v )s m a r t
systems responding to stimuli: including single and multiple
drug interventions and tissue therapies (e.g., angiogenesis,
wound healing, and artiﬁcial organs for autoimmune dis-
eases). The applications discussed in the following sections
demonstrate the breadth of nanotechnologies that impact
these release strategies. These all capitalize on how carefully
these drugs were designed, developed, and engineered for
desired properties and capabilities. Speciﬁcity of uptake,
clearance control, and ability to perform extremely diﬃcult
tasks, such as drug delivery to the brain via transport
across the blood brain barrier, the cerebrospinal ﬂuid, or
in smart implants, are highly desired capabilities. Coupling
advanced materials development and processing techniques
with nanoscience and technology creates innovative oppor-
tunitiesnotonlyfortraditionaldrugdeliverycapabilities,but
helps establish the impact platform technologies necessary
for tissue engineering/therapy methodologies.
2.3.1. Passive Delivery Mechanisms. These traditional
schemes are governed by classical thermodynamic and
transport phenomena principles. They are highly dependent
upon the physicochemical properties and geometric
features of a drug’s formulation. In addition to solubility
limits, size distribution, habit and morphology (when
applicable), compaction or encapsulation technique,
and diﬀusivity/mass transfer coeﬃcients are signiﬁcant
contributors to accomplishing a successful therapeutic
event. For example, nanosized APIs are more readily
distributed uniformly with an excipient and/or adjuvant.
They also exhibit greater dissolution rates than larger sized
entities having the same total mass of drug retained within
the product matrix. These methods utilize the dissolution
capabilities of the entrapping matrices. Variable release
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each layer having diﬀerent transport properties. The design
of release protocols for multiple APIs, sequenced for
optimum eﬃcacy and synergism, is thus straightforward.
Furthermore, nontherapeutic layers can be included to
(i) provide a delay mechanism, (ii) possibly be a barrier
for protection until arrival to the desired local or organ
system, and/or (iii) be a sacriﬁcial layer containing an
adjuvant or other functional component that would, for
example, pre-condition the microenvironment [33]. These
techniques have been well documented and need not be
reiterated here. Obvious extensions to these methods are
incorporated into implant systems with hindered diﬀusion
capabilities, in addition to facilitated delivery due to
targeting features. Demonstrated implementations of a few
of these, along with some conceptualizations are presented
below.
2.3.2. Functionalizing for Speciﬁcity and Facilitated Delivery.
Novel nanomaterials are designed to possess unique fea-
tures using molecular engineering concepts. Innovative drug
delivery protocols have evolved capitalizing on these and
recognizing the analogous processes present during success-
ful applications in related areas. Understanding the binding
properties and characterization of transport mechanisms
within modiﬁed hydrogels and biomembranes [34]p r o v i d e s
the bases for designing implants with entrapped vesicles and
thecontrolledrelease oftheircargoAPIs.Includedhereisthe
concept of pulsitile—release systems [10]; that is, the drug is
released as bolus pulses in well deﬁned time intervals (see
later section referring to future opportunities for additional
comment).
Therapies that require the sequencing of multiple drugs
can therefore be accomplished by logical extensions. As
examples; (i) amphoteric core-shell microgels, that is, con-
traphilic two compartment colloidal particles [35, 36] could
be used as smart systems; either as implants or chaperones,
(ii) the concept of chaperones within a larger vector could
also prove feasible; to minimize clearance of the smaller
entities, or their catabolism, prior to their uptake at diﬃcult
to reach sites such as to the brain and subsequent transport
across the blood brain barrier, and (iii) stimulate angiogen-
esis through release of multiple cytokines (growth factors)
from nanovesicles entrapped in functionalized hydrogel
beads used as immunoprotective barriers for tissue therapy
applications [37–41]. Additional details with respect to the
research studiesinvolvedinformulatingtheseextensions and
conceptualizations can be found in the following sections.
Transport and Drug Delivery through the Blood-Brain Barrier
and Cerebrospinal Fluid. There are multiple barriers in the
centralnervoussystemthatinhibitAPItherapies.Theblood-
brain barrier (BBB) and blood-CSF (cerebrospinal ﬂuid)
barriers are vascular in nature, whereas the other, the brain-
CSF barrier, exists between brain tissue and the CSF. The
wall of the cerebral microvessels in the brain parenchyma
constitutes the BBB. Due to its unique structure it maintains
very low permeability to water and solutes. The multicell
layer present in the middle of the brain parenchyma is
knownastheblood-CSFbarrier.Presentthereareventricular
cavities (ventricles) ﬁlled with CSF secreted by the epithelial
cellsofthe choroidplexus,a highlyvasculartissue with leaky,
fenestrated capillaries covered with ependymal epithelium,
which has relatively tight junctions. The third barrier, the
interface between the CSF and brain tissue, is unlike the
other two tight blood barriers since it is relatively leaky.
Since it does not prove to be a signiﬁcant resistance to mass
transport it is a probable route for drug delivery once the
transport issues with the other barriers are resolved. Given
that the area of the BBB is about 1000 times that of the
blood-CSF barrier, it is more important to circumvent its
impermeability, and therefore that is the focus for continued
discussion [42]. Furthermore, since it is not considered as
limiting as compared to the BBB, further discussions related
to CSF transport are not given here but can be found
elsewhere [43].
The transport of substances from capillary blood into
the brain tissue is dependent upon molecular size, lipid
solubility, binding to speciﬁc transporters, and electrical
charge [44]. Compared to the peripheral microvessel wall,
the additional structure of the BBB and tighter endothelial
junctions greatly restricts transport of hydrophilic molecules
through the gaps between the cells, that is, the paracellular
pathway of the BBB [45]. In contrast, small hydrophobic
molecules such as O2 and CO2 diﬀuse freely across plasma
membranes following their concentration gradients, that
is, the transcellular lipophilic diﬀusion pathway. The BBB
permeabilitytomost moleculescanbeestimated on thebasis
of their octanol/water partition coeﬃcients. For example,
diphenhydramine (Benadryl), which has a high partition
coeﬃcient, can cross the BBB with relative ease, whereas
water-soluble loratadine (Claritin) is blocked. However, the
octanol/water partition coeﬃcients do not completely reﬂect
solute transport. Some soluteswith low partition coeﬃcients
easily cross the BBB by active or facilitated transport mech-
anisms, which rely on ion channels, speciﬁc transporters,
energy-dependentpumps, and alimited amount ofreceptor-
mediated transcytosis. Small drug molecules analogous to
glucose, amino acids, and small intermediate metabolites,
for example, reach brain tissue via facilitated transport
mediated by speciﬁc transport proteins, whereas larger
molecules, such asinsulin and otherprotein typetherapeutic
agents, are carried across the BBB via receptor-mediated or
adsorptive transcytosis. Furthermore, some small molecules
with high octanol/water partition coeﬃcients are seemingly
blocked. Thorough data analysis suggests that they are
actively pumped back into the blood by eﬄux systems. For
instance, members of the adenosine triphosphate-binding
cassette family of exporters are potent energy-dependent
transporters. They contribute greatly to the eﬄux of xeno-
biotics and due to this protective role impede the delivery
of therapeutic agents. Consequently, to develop eﬀective and
eﬃcient methods for drug delivery to the brain through the
BBB,itisimperative tocontrolitspermeability.Thisrequires
understanding the mechanism by which these structural
components, as well as transporters, receptors, eﬄux pumps
and othercomponentsatthe endotheliumand astrocyte foot
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Various methods such as intracerebral implantation,
microdialysis, convection-enhanced distribution (CED),
osmotic shock, and chemical modiﬁcation of the BBB
have been developed for delivering drugs into the brain.
However, the applications of these methods are limited
and they can only partially keep with the demands of
modern therapies. For instance, the eﬃciency of intracere-
bral implantation, microdialysis and CED methods are low
since their major transport mechanisms are diﬀusion and
convectionofinterstitial ﬂuid.ForeﬀectivetreatmentofCNS
diseases, an adequate amount of therapeutic agents must
reach the speciﬁc regions of the brain. As discussed earlier,
functionalized target chaperones have this ability. They can
directly deliver therapeutic agents via these transporters by
closely mimicking their substrates, or conjugating the drugs
to ligands of the speciﬁc surface receptors expressed for
transcytosis (receptor-mediated transcytosis, RMT-Trojan
horse approach). Furthermore, these functionalized target
chaperones are used in delivering cationized proteins, pep-
tides, and as nanoparticle carriers for adsorptive mediated
transcytosis (AMT).
Although the exact mechanisms of RMT are not fully
understood, the development of drug delivery protocols
using receptor targeting has been successful [46–50]. This
physiological approach is often referred to as the molecular
Trojan horse approach since the therapeutic compounds are
delivered to speciﬁc sites for transcytosis by various forms of
vectorcarriers.Thisapproachalsoimprovesthedrugloading
capacity. The technique is very promising, but unfortunately
there remain a number of hurdles to overcome [48–50]. In
particular,evenifthetotalamountofdrugtransported tothe
brain is large, most of it may not be eﬃcacious since it might
remain associated with brain microvessel endothelial cells
and not reach the brain parenchyma. If drug translocation is
accomplished by conjugation with an antibody, there exists
the challenge of dissociation due to the high aﬃnity of
antibodies. Furthermore, speciﬁcity for uptake in the brain
may be compromised since the BBB receptors utilized there
could also have a widespread distribution on peripheral
organs; in eﬀect, resulting in a seemingly nonspeciﬁc uptake.
Not only will this limit eﬃcacy, but could induce additional
toxicity.
Improvements in Encapsulation Technologies for Tissue Thera-
pies. The success of an implant protocol utilizing entrapped
tissue for a therapeutic intervention is highly dependent
upon controllability of transport characteristics and the
microenvironment [33]. Improving the oxygen supply to
encapsulated insulin producing cells has been selected for
illustration. The basic concepts are to improve the per-
meability of the encapsulating hydrogel and maintain a
high oxygen partial pressure in the surrounding microen-
vironment. A number of approaches have been suggested,
with some tested and validated [51]. Those that utilize
nanotechnology, with their inherent improvement qualities,
are the focus in this section. The results of two independent
studiesthataddresstheindividualconceptsmentionedabove
willbediscussedbrieﬂy.Whencoupledtheyshouldprovidea
synergistic response. Permeability enhancement was accom-
plished by entrapping a perﬂuorocarbon nanoemulsion
within the hydrogel capsule [51]. Oxygen supply to the cap-
sule surfaces was enhanced through greater vascularization
in the microenvironment by stimulation of angiogenesis by
cytokines released from the implant [37–41]. Use of cargo-
loaded functionalized nanovesicles that control individual
cytokine release rates is an obvious extension to that work.
One important goal of these angiogenesis studies was to
quantitatively evaluate the rates at which diﬀerent individual
growth factors (GFs) are released from their hyaluronic
acid hydrogel implants. The ability of added amounts
of heparin to speciﬁcally regulate basic ﬁbroblast growth
factor (bFGF) or vascular endothelial growth factor (VEGF),
release from their gels without loss of ability to stimulate a
neovascularization response was investigated both in vitro
and in vivo. For both of these growth factors, the rate of
release declinedmonotonically withincreasing heparin (Hp)
content. As little as 0.03% w/w Hp signiﬁcantly moderated
the time course of release, while inclusion of 0.3% Hp
resulted in sustained release over several weeks [40].
Theresultsofthatstudysuggest thepossibilityofdelivery
of growth factors in speciﬁed sequences at regulated rates,
simply by controlling the composition of the gels. Inclusion
of as little as 0.3% Hp in the gels led to signiﬁcant diﬀerences
in the rates of release of individual GFs. By taking advantage
of those diﬀerences, it may be possible to design implants
that are capable of both storing and providing sustained,
localized in vivo release of the growth factors, without loss
of their biologic eﬀectiveness.
Co-delivery of a combination of more rapidly released
GFs together with more slowly released factors may then
permit engineered control of desired physiologic processes
such as angiogenesis through use of this selective release
sequence concept.
The Johnson et al. study [51]i sa ne x a m p l et h a t
illustrates the usefulness of permeability enhancement,
through nanotechnology techniques, for delivery of tissue
based therapeutic agents. Their eﬀorts were to enhance the
performance of a bioartiﬁcial pancreas to treat diabetes
that uses microencapsulation as an immune barrier for
transplanted islets of Langerhans. Unfortunately, the barrier
also imposes oxygen diﬀusional limitations that can result in
loss of viability and function. It is critical that the necessary
amount of oxygen be delivered to encapsulated tissue after
transplantation in order to maintain normal levels of insulin
secretion. Without a solution that allows for eﬀective oxygen
delivery, transplantation of encapsulated tissue may never be
successful.
Their investigation included methods to reduce oxygen
transport limitations by enhancing encapsulant oxygen per-
meability, for example, by combination of a highly concen-
trated perﬂuorocarbon (PFC) nanoemulsion with alginate
(PFC alginate). A theoretical reaction—diﬀusion model was
used to predict the three-dimensional distribution of oxygen
partial pressure in a spherical microcapsule and a planar slab
containing islet tissue, from which the loss of cell viability
and the reduction in insulin secretion rate are estimated.
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and PFC alginate to examine the eﬀect of surface oxygen
partial pressure, capsule diameter, slab thickness, and the
size and density of dispersed islet tissue. Results show
that hypoxic conditions can be reduced, thereby enhancing
islet viability and substantially maintaining insulin secretion
rate when the PFC nanoemulsion is incorporated in the
encapsulation material for both geometries.
The approach was also evaluated experimentally, and
the ability to enhance encapsulated tissue survival and
function was successfully demonstrated, both in vitro and
in vivo. Intact islets encapsulated in normal alginate and
in PFC alginates having the composition described in the
numerical predictions were used as model systems. Recovery
of viable tissue after culture under various O2 partial pres-
sure conditions was expressed as the oxygen consumption
rate (OCR)/unit volume of capsule divided by the same
parameter measured immediately after encapsulation and
before culture. When cultured at very low pO2,f r a c t i o n a l
OCR recovery was substantially greater with PFC alginate
than with normal alginate. Furthermore, examination of
histological sections revealed necrosis in some islets in
normal alginate capsules cultured at 3.5 and 142mmHg,
whereas no necrosis was observed in islets within PFC
alginatecapsules.Theﬁndings andinsightsgainedfromboth
the theoretical and experimental studies will increase the
probability of a successful cell therapy for the treatment of
diseases such as diabetes.
Theconceptof“backpacks”discussedearlierwithrespect
to drug chaperones can also be applied to encapsulation
techniques and tissue therapies. The commonality rests
with the use of nanofabrication approaches to create these
entities,forexample,thephotolithographicmethodreported
previously [31, 32]. The product of this manufacturing
step can be either the cell-backpack complexes or freely
suspended backpacks. Since these backpacks can carry a
myriad of compounds with diﬀering functionalities, their
applications seem boundless. Of particular interest here
with respect to tissue engineering is the ability of these
freely suspended backpacks to promote cell aggregate self-
assembly. The size of these aggregates, as inﬂuenced by
backpack diameter and ratio of cells to backpacks in the
culture medium, has been shown to be reproducible [32].
Furthermore, the binding strength is quite strong; which
was demonstrated by forcing the complexes through small
pores and noting that the backpacks were not removed
from the surface of the cells. The importance lies in the
ability to use injection techniques (as in a needle tip of a
syringe assemble), or for the movement from blood to tissue
(extravasation) via narrow gaps. Based on these successes,
one can envision applications that would create organoids
of various types, such as lymphoid and beta cell clusters
(analogous to islet of Langerhans). In these cases, the cargo
could consist of drugs, adjuvants, and/or growth factors
(forangiogenesis stimulation, reproduction, etc.).There also
appears the potential for wound healing protocols.
To support our conjectures, some speciﬁc results should
be elucidated. In their paper [32], the Cohen group presents
fundamental studies on forming cellular aggregates using
injectable cellular backpacks, how to control aggregate size,
and observations on association strength. Using confocal
microscopy, ﬂow cytometry, and laser diﬀraction, they
observedthat,while verylarge(>1mm) aggregates can form,
t h e ym a ya l s od i s s o c i a t ea n dr e f o r m .A g g r e g a t e sw e r ef o r c e d
through a nylon mesh ﬁlter and observed afterward: as
the ﬁlter size decreased, resultant aggregates were smaller.
When the pore size was reduced to less than the diameter
of an individual cell, the backpacks were still attached.
This implied to them that the attachment is suﬃciently
strong such that the backpacks would remain attached to a
lymphocyte undergoing extravasation in vivo. In conclusion,
they feel that an injectable backpack system could have
applications in lymphoid tissue engineering as described by
others [52, 53], as well as more general cellular engineering
applications requiring close cell association.
3.ChallengesandFutureOpportunities
In this section, challenges such as safety considerations and
reformulation strategies to overcome loading limitations,
overdosing, and clearance issues are addressed. The oppor-
tunities lie in the enhanced capabilities with respect to
improves therapeutic intervention strategies and additional
applications for nanomedicine in the healthcare sector.
The perception that nanomaterials have inherent incom-
patibility issues with respect to the uptake into the
human systemic environment has been addressed by many
nanobiotechnology researchers (see Zook et al. [54]f o ra
representative paper from the Biochemical Science Division
of the National Institute of Standards and Technology).
Concerns such as toxicity, leaching, clearance, repro-
ducibility/nonuniformity, chaperone characteristics/use of
surface active agents and stability are major factors aﬀecting
the revolutionization of nanomedicine. The presence of
multiple nanotechnology based drugs in the market place
attests to the resolution of many of these issues. However,
many more related to bioeﬃcacy, loading capacity, and
other features associated with performance optimization
presentongoingchallengesandopportunitiesforadvancesin
nanomedicine thereby ensuring that it represents the future
of medical care. General discussions, with key literature
references, can be found in sources such as the Biomedical
Engineering Handbook [55]. Of particular interest would
be the section devoted to bionanotechnology with speciﬁc
articles related to nanomaterials: perspectives and possibil-
ities in nanomedicine [56]. The following comments are
excerpts from their work and that of many other previously
mentioned researchers [1–10, 31, 32, 35, 45, 52], along with
summary statements from previous sections of this paper.
Speciﬁc illness treatments via nanomedicine protocols
each have unique detriments that can be remedied by
providing a range of delivery systems. The concept is to
develop methods of controlled therapeutic delivery and
release to speciﬁc tissues and tumors over a desired timeline.
These systems are designed speciﬁcally to deliver soluble
drugs, proteins, vaccine adjuvants, and plasmid DNA for
gene therapy by exposing target cells to their cargo. The
chaperone is thus required to enter the cells via endocytic12 Journal of Drug Delivery
or phagocytic pathways and release its payload through
degradation and diﬀusion mechanisms. The major challenge
here is to accomplish these tasks while addressing the issues
of biocompatibility, biodegradation, and the capture and
clearance by the reticuloendothelial system (RES). Although
excelling at some aspects, the current systems often fail
to incorporate all required characteristics for high in vivo
performance.
Thechaperones fortherapeuticnanoentities includeviral
carriers, organic and inorganic nanoparticles, and peptides.
Although the eﬃcient targeted delivery of therapeutic drugs
continues to present challenges (with tremendous poten-
tial beneﬁts), the emerging research into proteomics, for
gene therapy as the future of nanomedicine treatments is
attracting more attention. Fortunately, the necessary gene
transfection considerations are directly applicable to drug
delivery systems also.
The current carriers used for transfection are mainly
adeno- and retroviruses. Although highly eﬃcient they pose
immunogenic and mutagenic hazards which led researches
to seek nonviral vectors. These include liposomes and
nanoparticles of peptides and polymers, both synthetic and
natural.Selectionofvectortypeisdictatedbythetherapeutic
agent, required pharmacokinetics, and the target cellular
system, in addition to physical properties such as zeta
potential (positive surface charge). The binding to blood
proteins, clearance by the RES, and circulation times in the
range of hours, rather than minutes, can be key performance
targets/speciﬁcations.Hydrophilicpolyethyleneglycol(PEG)
or longer chain polyethylene oxide (PEO) are commonly
used synthetic polymers. Chitosan and alginate are useful
natural polymers due to their excellent biodegradability
characteristics. Biocompatible peptides show signiﬁcant
p r o m i s es i n c et h e ya r ea b l et ob y p a s st r a d i t i o n a le n d o c y t i c
pathways. Speciﬁc details can be found in Douglas et al. [56]
and their accompanying literature references. The practical
considerations enumerated there stress the need for the
control of zeta potential, surface functionality via physical
and chemical modiﬁcations, and the attainment of desired
sizing. The method used to determine size is also important
since dynamic light scattering (DLS) frequently gives larger
measurementvaluesthanelectronmicroscopy.Furthermore,
DLS is particularly dependent on the presence of aggregate-
inducing ions and proteins.
Vehicle surface characteristics are essential to control the
contact time these vectors remain in the vasculature of a
targetregionwithrespect toendocytosisand/orcargorelease
kinetics. Thus, in addition to chemical functionalization
there exists numerous opportunities for magnetic, heat, and
light aﬀected systems inﬂuenced by external stimulus/ﬁelds.
These technological advances will translate into signiﬁ-
cant market enhancements. This is clear for both new and
old drugs. For example, nanosizing of current marketed
products is a means of providing these old drugs a new
deliveryplatformoﬀeringnewbeneﬁtsandimprovedperfor-
mance. FDA records indicate that the majority of approvals
are reformulations or combinations of previously approved
products. As a new candidate proceeds through its clinical
testing program, it can be reﬁned and/or postprocessed from
its discovery formulation to meet the requirements of the
emerging target product proﬁle; that is, its delivery route,
dosage, and pharmacokinetic behavior.
Considering its vast potential it becomes evident that
nanotechnology will have a signiﬁcant impact upon the drug
delivery sector and its ability to provide sound technological
solutions for drug development programs. Consequently,
market expectations for the nanotechnology drug delivery
platform are high, and it is estimated that it will increase to
about $ 16 billion (USD) by 2014 [10].
4.Conclusions
Novel nanomaterial manufacturing methods and emerging
nanotechnology applications for the pharmaceutical indus-
try have been discussed in this paper. These manufacturing
methods combine features such as bottom up nanoparticle
formation for control of size and crystal structure with con-
tinuous manufacturing and Process Analytical Technology
(PAT) for quality control and compatibility with the strict
requirements imposed upon the pharmaceutical industry.
The production of carefully engineered nanoparticles pro-
ducedathighthroughputratesandelevatedtechnoeconomic
stature demonstrates the role that transport phenomena has
in path forward approaches for advanced drug delivery.
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